2021
DOI: 10.1007/s11095-021-03157-y
|View full text |Cite
|
Sign up to set email alerts
|

Excipient Innovation Through Precompetitive Research

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 10 publications
0
6
0
Order By: Relevance
“…In general, quantitative NMR analysis often relies on some linearity between an NMR parameter and the solute amount. 23,24 As we have shown previously, 14,25 in the absence of aggregation, R 2 ( 1 H 2 O) shows a linear dependence on the concentration of a solute. In the presence of aggregates, the concentration dependence of R 2 ( 1 H 2 O) deviates from linearity.…”
mentioning
confidence: 54%
See 3 more Smart Citations
“…In general, quantitative NMR analysis often relies on some linearity between an NMR parameter and the solute amount. 23,24 As we have shown previously, 14,25 in the absence of aggregation, R 2 ( 1 H 2 O) shows a linear dependence on the concentration of a solute. In the presence of aggregates, the concentration dependence of R 2 ( 1 H 2 O) deviates from linearity.…”
mentioning
confidence: 54%
“…Indeed, under conditions of controlled stress, such as heat-induced protein aggregation at fixed temperature but with variable exposure time, one might observe a fairly linear dependence of Z-average R h on the percentage content of protein aggregates. 14,15 In our previous paper, 16 we demonstrated that the water proton transverse relaxation rate R 2 ( 1 H 2 O) could be used to detect the presence of monoclonal antibody (mAb) aggregates generated by different stresses. Compared to SEC, MFI, and DLS, the water proton NMR (wNMR) approach was consistently sensitive to changes in protein aggregate populations, both soluble and insoluble aggregates and subvisible particles.…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…153 In addition, the transport and distribution of many biological therapies requires what is termed the 'cold-chain', that is they must remain refrigerated or frozen during each step of the physical delivery process, from the manufacturing location to the clinical administration site. 154 This can be particularly problematic when considering restrictions associated with therapeutic distribution in low-and middle-income countries, as highlighted by the recent and on-going distribution of vaccines for COVID-19. 155 Finally, storage and shelf life are also a major consideration for all therapeutic agents developed.…”
Section: Advantages and Disadvantages Of Ampsmentioning
confidence: 99%